Drug Research

CDMOs Offering Unique Options To Meet Cold Chain Demands

It is worth noting that the Cell and gene therapies- CGTs have gone on to show immense promise when it comes to treating diverse conditions, right from cancer to neurodegenerative diseases. But, alongside their potential perks, they go on...

Asahi Kasei Bioprocess and Axolabs Announce Strategic Partnership to Accelerate Oligonucleotide Therapeutics Development

Asahi Kasei Bioprocess America, Inc (AKB), part of the Asahi Kasei Group, and Axolabs have announced a strategic partnership in the burgeoning field of oligonucleotide therapeutics. The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility spanning...

QIAGEN receives approval for NeuMoDx HIV-1 Quant assay in Thailand for blood-borne virus testing

QIAGEN announced that its NeuMoDx human immunodeficiency virus type 1 (HIV-1) assay has received approval for use in Thailand. Along with the previously approved hepatitis B virus (HBV) and hepatitis C virus (HCV) quantitative assays there is now a...

Drug Delivery – Switchable Peptide-Stabilized Emulsions

A new study which has been led by Prof. Meital Reches from the Hebrew University, along with Mr. Daniel Boas, one of the Ph.D. students in her group, as well as the team of collaborators, has gone on to...

Advancements In Drug Delivery Strengthen Health of Women

Right from elevating the contraceptive methods to going ahead and improving the treatment of reproductive health issues, drug delivery innovations happen to be paving the way for a more personalized as well as an effective approach to women’s healthcare. Numerous...

Targeted Drug Delivery Enabled By Novel Molecular Device

In one of the newly brought up breakthroughs that could go ahead and even revolutionize medical as well as material engineering, scientists have gone on to develop a first-of-its-kind molecular device that goes ahead and controls the release of...

mRNA Treatment May Swap Rare Illness Intracellular Proteins

Notably, the interim data from a Phase I/II clinical trial goes on to suggest that mRNA-3927, which happens to be an investigational mRNA therapy from Moderna, can very well be a promising treatment when it comes to propionic acidaemia. A...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read